Incannex Healthcare Inc. (NASDAQ:IXHL – Get Free Report) saw a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 21,688,567 shares, an increase of 29.9% from the January 15th total of 16,695,670 shares. Currently, 6.3% of the company’s stock are short sold. Based on an average daily trading volume, of 7,462,617 shares, the short-interest ratio is currently 2.9 days. Based on an average daily trading volume, of 7,462,617 shares, the short-interest ratio is currently 2.9 days. Currently, 6.3% of the company’s stock are short sold.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Incannex Healthcare in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.
Read Our Latest Stock Report on IXHL
Institutional Trading of Incannex Healthcare
Incannex Healthcare Price Performance
Incannex Healthcare stock opened at $0.26 on Wednesday. The stock has a market capitalization of $90.54 million, a price-to-earnings ratio of -0.44 and a beta of 7.46. Incannex Healthcare has a 1-year low of $0.08 and a 1-year high of $1.82. The business has a fifty day moving average price of $0.36 and a 200-day moving average price of $0.42.
Incannex Healthcare (NASDAQ:IXHL – Get Free Report) last announced its earnings results on Friday, February 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02).
About Incannex Healthcare
Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.
The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation.
Featured Stories
- Five stocks we like better than Incannex Healthcare
- Energy Security Is Now National Security – Positioning Is Happening Now
- The gold chart Wall Street is terrified of…
- Your Bank Account Is No Longer Safe
- This $15 Stock Could Go Down as the #1 Stock of 2026
- [How To] Invest Pre-IPO In SpaceX With $100!
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
